Meanwhile, BioNTech intends to start mid-stage trials of two more cancer vaccines – FixVac candidate BNT113 for head and neck cancers and Genentech-partnered individualised neoantigen specific ...

Of these, BNT111 and BNT113 lead the way, as phase 2 studies started in mid-2021 after promising early results. These mRNA-based therapies were produced with BioNTech's FixVac technology ...

BioNTech is expanding its oncology pipeline ... In my opinion, the following are quite promising: BNT111 for advanced melanoma, BNT113 for HPV16+ (a type of human papillomavirus [HPV]), and ...

BioNTech gets the opportunity to tap into the ... headed by BNT111 for melanoma and BNT113 for head and neck cancer in phase 2. The idea is to use mRNA sequences in the shot that target multiple ...

BioNTech has a 52-week low of $76.53 and a 52 ... BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck ...